For a 5-year-old boy with unexplained bruising and a family history of bleeding, which treatment option is appropriate based on laboratory results showing a Factor VIII level of 60%?

In this scenario, the treatment option of DDAVP (Desmopressin) is appropriate for the 5-year-old boy with a Factor VIII level of 60%, which indicates that he has mild hemophilia A. DDAVP is a synthetic analog of vasopressin that stimulates the release of von Willebrand factor (vWF) from endothelial cells. This promotes the release of endogenous Factor VIII, thereby increasing its levels in the circulation.

With a Factor VIII level of 60%, the boy may experience some bleeding tendencies, but his levels are not severely deficient. DDAVP is particularly effective in patients with mild hemophilia A or von Willebrand disease because it can safely elevate the Factor VIII levels when needed, making it a first-line treatment option. In mild cases, DDAVP can significantly reduce bleeding episodes without the need for more invasive treatments or factor replacement therapy.

The other treatment options are not as suitable in this case. Factor VIIa is typically used for hemophilia patients who have inhibitors and is not indicated for this patient with normal anti-hemophilic factor levels. Factor IX concentrate is mainly used for hemophilia B, which involves a deficiency of Factor IX, not Factor VIII. Fresh Frozen